Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
about
Perspectives on antiviral use during pandemic influenzaThe Role of Neuraminidase Inhibitors in the Treatment and Prevention of InfluenzaComparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza virusesComparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza virusesHigh-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase ActivityPlanning for the next pandemic of influenza.Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.Recent progress and challenges in the discovery of new neuraminidase inhibitors.Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitorPhenotypic drug susceptibility assay for influenza virus neuraminidase inhibitorsOverexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitorsEvaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.Neuraminidase inhibitors: zanamivir and oseltamivir.Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalationSelective incorporation of influenza virus RNA segments into virions.Spotlight on zanamivir in influenza.Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.Animal models for the study of influenza pathogenesis and therapy.Influenza neuraminidase: a druggable target for natural products.Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza.Zanamivir: an influenza virus neuraminidase inhibitor.Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.Strategies in the Design of Antiviral Drugs
P2860
Q24522384-0E97AA29-4B23-4501-8AC2-00CBD82B9B2CQ24793414-118341F0-0BDB-4B84-9FCF-8037331018F3Q28353147-72408EFD-D2D3-41C3-A1D6-8C3A06BC5D34Q28364114-30DA5E07-93A5-416D-8BD8-FFE2F4740FFEQ28472513-ED9E4574-CE59-4FC4-88BA-EB9CD35554CAQ28552500-2F85696A-342E-493E-80F2-CF42A64A7C52Q30327977-DF8252C0-6E20-4A31-A24B-82674073D892Q30404038-C9EFC50A-C9C4-48EE-BD90-7B3158DEC85EQ30426630-BED69AD5-4198-44A8-810E-B0B20B5147E3Q30448118-9080D9A7-20F1-41CE-B633-5B8D31D25FD2Q30450742-58DF6BAD-F3BB-4C7E-882E-29C26D653B19Q30452892-489F091F-240A-4AF9-9E20-C76FA5A97E51Q30453005-5AFF891B-1ECB-4D08-867E-3CFE5109DF3AQ31989695-DF4CBA98-873D-4282-971D-B37838B8DD5BQ33826384-16D67AD6-E2B6-46A5-973C-216BC8EF7548Q33980106-0444D517-BC43-4F3F-8F05-753C786E8B68Q34762920-33BEB24E-E4E0-4679-872C-4F3C7C087B34Q35627901-E3FEE9B9-AB5D-4732-97D6-E92899FD5F56Q36281137-29A399F0-C404-47AC-BF1F-DC4524DD9EF9Q37335679-E768A024-44FE-45FD-BB6B-5532647A6535Q37379466-83D07AD0-A5E3-4BF2-9AE1-86C70DB1097DQ37949284-222EE357-16E1-4F2E-97DD-8AE95BF19A26Q39651456-41447D5A-2DC9-4FEE-A13C-2A8DC4032098Q39766159-94FBEE3B-67AD-485A-88DE-076549E5C938Q40419399-05B4AB40-BB8C-42A2-96E1-5A24FE54BA78Q43975411-CFC5B24F-CF7F-4B24-B2CE-11A96CC3D019Q56786281-258E5E18-C350-4BB2-982B-EBC9B60F9D7B
P2860
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Zanamivir susceptibility monit ...... II clinical efficacy studies.
@ast
Zanamivir susceptibility monit ...... II clinical efficacy studies.
@en
type
label
Zanamivir susceptibility monit ...... II clinical efficacy studies.
@ast
Zanamivir susceptibility monit ...... II clinical efficacy studies.
@en
prefLabel
Zanamivir susceptibility monit ...... II clinical efficacy studies.
@ast
Zanamivir susceptibility monit ...... II clinical efficacy studies.
@en
P2093
P2860
P1476
Zanamivir susceptibility monit ...... II clinical efficacy studies.
@en
P2093
A D Osterhaus
G F Rimmelzwaan
J M Barnett
P2860
P356
10.1128/AAC.44.1.78-87.2000
P407
P577
2000-01-01T00:00:00Z